• Geoffrey M. Clarke


Sepsis, a systemic inflammatory response to an infectious agent, is a major cause of morbidity and mortality in critically ill patients. If not recognized and treated promptly, sepsis can progress to severe sepsis, septic shock, multiple-organ dysfunction, and death.


Septic Shock Severe Sepsis Mean Arterial Pressure Systemic Inflammatory Response Syndrome Pulmonary Capillary Wedge Pressure 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sibbald WJ, Marshall J, Christou N, Girotti M, McCormack D, Rostein O, Martin C, Meakins J. “Sepsis” — clarity of existing terminology…or more confusion? Crit Care Med 1991; 19: 996–8.PubMedCrossRefGoogle Scholar
  2. 2.
    American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864–74.Google Scholar
  3. 3.
    Ledingham I MCA, Badley JA. Update in host defense mechanisms. In: Update in Intensive Care and Emergency Medicine, Vincent JL, ed. Berlin: Vincent JL, ed. 1988; 5: 65–7.Google Scholar
  4. 4.
    Vincent JL, Bihari DJ, Suter PM, Bruning HA, White J, Nicolas-Chanoin MH, WolffM, Spencer RC, Hemmer M. The prevalence of nosocomial infection in intensive care units in Europe, Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274: 639–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Craven DE, Kunches LM, Lichtenberg DA, Kollisch NR, Barry MA, Heeren TC, McCabe WR. Nosocomial infection and fatality in medical and surgical intensive care unit patients. Arch Intern Med 1988; 148: 1161–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Banerjee SN, Emroi TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson J, Henderson T, Martone WJ. Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989, National Nosocomial Infections Surveillance System. Am J Med 1991; 91 (3B): 86S - 89S.PubMedCrossRefGoogle Scholar
  7. 7.
    Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990, National Nosocomial Infections Surveillance System. J Infect Dis 1993; 167: 1247–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Wiles JB, Cerra FB, Siegel JH, Border JR. The systemic septic response: does the organism matter? Crit Care Med 1980; 8: 55–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Abraham E. Physiologic stress and cellular ischemia: relationship to immunosuppression and susceptibility to sepsis. Crit Care Med 1991; 19: 613–8.PubMedCrossRefGoogle Scholar
  10. 10.
    de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, to Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, deVries JE. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Browder W, Williams D, Pretus H, Olivero G, Enrichens F, Mao P, Franchello A. Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg 1990; 211: 605–12.PubMedGoogle Scholar
  12. 12.
    Hamilton G, Hofbauer S, Hamilton B. Endotoxin, TNF-(, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis 1992; 24: 361–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24: 1125–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Doughty L, Patrene K, Boggs S, Tahara H, Robbins P. Suppression of native IL-10 production by constitutive expression of viral IL-10 (vIL-10) or soluble TNF receptor p75 (sTNFR) in mice. Crit Care Med 1996; 24 (Suppl): A32.CrossRefGoogle Scholar
  15. 15.
    Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-(concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24: 381–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Bone RC. Gram positive organisms and sepsis. Arch Intern Med 1994; 154: 26–34.PubMedCrossRefGoogle Scholar
  17. 17.
    Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP. Septic shock in humans. Advances in understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann Intern Med 1990; 113: 227–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Astiz ME, Galera-Santiago A, Rackow EC. Intravascular volume and fluid therapy for severe sepsis. New Horiz 1993; 1: 127–36.PubMedGoogle Scholar
  19. 19.
    Wilson RF. The diagnosis and management of severe sepsis and septic shock. Heart Lung 1976; 5: 422–9.PubMedGoogle Scholar
  20. 20.
    James JH, Fang CH, Schrantz SJ, Hasselgren PO, Paul IU, Fischer JE. Linkage of aerobic glycolysis to sodium-potassium transport in rat skeletal muscle. Implications for increased muscle lactate production in sepsis. J Clin Invest 1996; 98: 2388–97.PubMedCrossRefGoogle Scholar
  21. 21.
    Cortez A, Zito J, Lucas CE, Genick SJ. Mechanism of inappropriate polyuria in septic patients. Arch Surg 1977; 112: 471–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Parker MM, Shelhamer JH, Natanson C, et al. Serial haemodynamic patterns in survivors and non- survivors of septic shock in humans. Clin Res 1983; 31: 671A.Google Scholar
  23. 23.
    Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109–42.PubMedGoogle Scholar
  24. 24.
    Wang P, Ba ZF, Cioffi WG, Bland KI, Chaudry IH. The pivotal role of adrenomedullin in producing hyperdynamic circulation during the early stage of sepsis. Arch Surg 1998; 133: 1298–304.PubMedCrossRefGoogle Scholar
  25. 25.
    Nishio K, Akai Y, Murao Y, Doi N, Veda S, Tabuse H, Miyamoto S, Dohi K, Minamino N, Shoji H, Kitamura K, Kangawa K, Matsuo H. Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med 1997; 25: 953–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Hess ML, Hastillo A, Greenfield LJ. Spectrum of cardiovascular function during gram negative sepsis. Prag Cardiovasc Dis 1981; 23: 279–98.CrossRefGoogle Scholar
  27. 27.
    Sibbald WJ, Paterson NA, Holliday RL, Anderson RA, Lobb TR, Duff JH. Pulmonary hypertension in sepsis: measurement by the pulmonary arterial diastolic-pulmonary wedge pressure gradient and the influence of passive and active factors. Chest 1978; 73: 583–91.PubMedCrossRefGoogle Scholar
  28. 28.
    Ognibene FP, Parker MM, Natanson C, Shelhamer JH, Parillo JE. Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. Chest 1988; 93: 903–10.PubMedCrossRefGoogle Scholar
  29. 29.
    Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J Clin Invest 1992; 90: 389–98.PubMedCrossRefGoogle Scholar
  31. 31.
    Ellrodt AG, Riedinger MS, Kimchi A, Berman DS, Maddahi J, Swan HJ, Murata GH. Left ventricular performance in septic shock: reversible segmental and global abnormalities. Am Heart J 1985; 110: 402–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parillo JE. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100: 483–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JJ, Parillo JE. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest 1986; 78: 259–70.PubMedCrossRefGoogle Scholar
  34. 34.
    Hayes MA, Timmins AC, Yau EH, Palazzo M, Watson D, Hinds CJ. Oxygen transport patterns in patients with sepsis syndrome or septic shock: influence of treatment and relationship to outcome. Crit Care Med 1997; 25: 926–36.PubMedCrossRefGoogle Scholar
  35. 35.
    Parker MM, Shelhamer JH, Natanson C, Ailing DW, Parillo JE. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 1987; 15: 923–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Metrangolo L, Fiorillo M, Friedman G, Silance PG, Kahn RJ, Novelli GP, Vincent JL. Early hemodynamic course of septic shock. Crit Care Med 1995; 23: 1971–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Munt B, Jue J, Gin K, Fenwick J, Tweeddale M. Diastolic filling in human severe sepsis: an echocardiographic study. Crit Care Med 1998; 26: 1829–33.PubMedCrossRefGoogle Scholar
  38. 38.
    Cunnion RE, Schaer GL, Parker MM, Natanson C, Parillo JE. The coronary circulation in human septic shock. Circulation 1986; 73: 637–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Dhainaut JF, Huyghebaert MF, Monsallier JF, Lefevre G, Dall’Ava Santucci J, Brunet F, Villemant D, Carli A, Raichvarg D. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose and ketones in patients with septic shock. Circulation 1987; 75: 533–41.PubMedCrossRefGoogle Scholar
  40. 40.
    Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor-a and interleukin 1 are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996; 183: 949–58.PubMedCrossRefGoogle Scholar
  42. 42.
    Muller-Werdan U, Werdan K. Septic cardiomyopathy. Curr Opin Crit Care 1999; 5: 415–21.CrossRefGoogle Scholar
  43. 43.
    Abraham E, Shoemaker WC, Bland RD, Cobo JC. Sequential cardiorespiratory patterns in septic shock. Crit Care Med 1983; 11: 799–803.PubMedCrossRefGoogle Scholar
  44. 44.
    Gilbert EM, Haupt MT, Mandanas RY, Huaringa AJ, Carlson RW. The effect of fluid loading, blood transfusion and catecholamine infusion on oxygen delivery and consumption in patients with sepsis. Am Rev Respir Dis 1986; 134: 873–8.PubMedGoogle Scholar
  45. 45.
    Mizock BA. Alterations in carbohydrate metabolism during stress: a review of the literature. Am J Med 1995; 98: 75–84.PubMedCrossRefGoogle Scholar
  46. 46.
    Lang CH, Dobrescu C. Gram-negative infection increases noninsulin-mediated glucose disposal. Endocrinology 1991; 128: 645–53.PubMedCrossRefGoogle Scholar
  47. 47.
    Zeller WP, Teh SM, Sweet M, Goto M, Gottschalk ME, Hurley RM, Filkins JP, Hotmann C. Altered glucose transporter in mRNA abundance in a rat model of endotoxic shock. Biochem Biophys Res Commun 1991; 176: 535–40.PubMedCrossRefGoogle Scholar
  48. 48.
    Meszaros K, Lang CH, Bagby GJ, Spitzer JJ. Tumor necrosis factor increases in vivo glucose utilization of macrophage-rich tissues. Biochem Biophys Commun 1987; 149: 1–6.CrossRefGoogle Scholar
  49. 49.
    Levy B, Bollaert PE, Charpentier C, Nace L, Audibert G, Bauer P, Nabet P, Larcan A. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997; 23: 282–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Gore DC, Jahoor F, Hibbert JM, DeMaria EJ. Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Ann Surg 1996; 224: 97–102.PubMedCrossRefGoogle Scholar
  51. 51.
    Gammaitoni C, Nasraway SA. Normal lactate/pyruvate ratio during overwhelming polymicrobial bacteremia and multiple organ failure. Anesthesiology 1994; 80: 213–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Siegel JH, Greenspan M, Del Guercio LR. Abnormal vascular tone, defective organ transport and myocardial failure in human septic shock. Ann Surg 1967; 165: 504–17.PubMedCrossRefGoogle Scholar
  53. 53.
    Ince C, Sinaasappel M. Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Med 1999; 27: 1369–77.PubMedCrossRefGoogle Scholar
  54. 54.
    Mohsenifar Z, Goldbach P, Tashkin DP, Campisi DJ. Relationship between 02 delivery and 02 consumption in the adult respiratory distress syndrome. Chest 1983; 84: 267–71.PubMedCrossRefGoogle Scholar
  55. 55.
    Danek Si, Lynch JP, Weg JG, Dantzker DR. The dependence of oxygen uptake on oxygen delivery in the adult respiratory distress syndrome. Am Rev Respir Dis 1980; 122: 387–95.PubMedGoogle Scholar
  56. 56.
    Pinsky MR. Beyond global oxygen supply-demand relations: in search of measures of dysoxia. Intensive Care Med 1994; 20: 1–3.PubMedCrossRefGoogle Scholar
  57. 57.
    Marik PE, Varon J. The hemodynamic derangements in sepsis: implications for treatment strategies. Chest 1998; 114: 854–60.PubMedCrossRefGoogle Scholar
  58. 58.
    Russell JA, Phang PT. The oxygen delivery/consumption controversy. Approaches to management of the critically ill. Am J Respir Crit Care Med 1994; 149: 533–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Ruokonen E, Takala J, Kari A, Saxen H, Mertsola J, Hansen EJ. Regional blood flow and oxygen transport in septic shock. Crit Care Med 1993; 21: 1296–303.PubMedCrossRefGoogle Scholar
  60. 60.
    Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994; 272: 1354–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 1999; 27: 639–60.Google Scholar
  62. 62.
    Packman MI, Rackow EC. Optimum left heart filling pressure during fluid resuscitation of patients with hypovolemic and septic shock. Crit Care Med 1983; 11; 165–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Groenveld AB, Nauta JJ, Thijs LG. Peripheral vascular resistance in septic shock: its relation to outcome. Intensive Care Med 1988; 14: 141–7.Google Scholar
  64. 64.
    Schreuder WO, Schneider AJ, Groenveld AB, Thijs LG. Effect of dopamine vs norepinephrine on hemodynamics in septic shock. Emphasis on right ventricular performance. Chest 1989; 95: 1282–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Martin C, Viviand C, Arnaud S, Vialet R, Rougnon T. Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients. Crit Care Med 1999; 27: 1708–13.PubMedCrossRefGoogle Scholar
  66. 66.
    Rossaint R, Falke KJ, Lopez F, Slams K, Pison U, Zappol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328: 399–405.PubMedCrossRefGoogle Scholar
  67. 67.
    Denton MD, Chertow GM, Brady HR. “Renal-dose” dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996; 50: 4–14.PubMedCrossRefGoogle Scholar
  68. 68.
    Shoemaker WC, Bland RD, Appel PL. Therapy of critically ill postoperative patients based on outcome prediction and prospective clinical trials. Surg Clin North Am 1985; 65: 811–33.PubMedGoogle Scholar
  69. 69.
    Shoemaker WC, Appel PL, Kram HR. Role of oxygen transport patterns in the pathophysiology, prediction of outcome and therapy of shock. In: Bryan-Brown CW, Ayres SM, eds. Oxygen Transport and Utilization, Fullerton, Ca: Society of Critical Care Medicine 1987; 65–92.Google Scholar
  70. 70.
    Edwards JD, Brown GC, Nightingale P, Slater RM, Faragher EB. Use of survivors’ cardiorespiratory values as therapeutic goals in septic shock. Crit Care Med 1989; 17: 1098–103.PubMedCrossRefGoogle Scholar
  71. 71.
    Tuchschmidt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992; 102: 216–20.PubMedCrossRefGoogle Scholar
  72. 72.
    Yu M, Levy MM, Smith P, Takiguchi SA, Miyasaki A, Myers SA. Effect of maximizing oxygen delivery on morbidity and mortality in critically ill patients: a prospective, randomized, controlled study. Crit Care Med 1993; 21: 830–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330: 1717–22.PubMedCrossRefGoogle Scholar
  74. 74.
    Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 1995; 333: 1025–32.Google Scholar
  75. 75.
    Bone R. Why sepsis trials fail. JAMA 1996; 276: 565–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Porter SB. Current status of clinical trials with anti-TNF. Chest 1997; 112: 339S-341 S.Google Scholar
  77. 77.
    Vincent JL. New therapies in sepsis. Chest 1997; 112: 330S - 338S.PubMedCrossRefGoogle Scholar
  78. 78.
    Natanson C, Esposito CJ, Banks SM. The sirens’ songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 1998; 26: 1927–31.PubMedCrossRefGoogle Scholar
  79. 79.
    Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999; 25: 556–66.PubMedCrossRefGoogle Scholar
  80. 80.
    Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976; 184: 333–41.PubMedCrossRefGoogle Scholar
  81. 81.
    Bernard GR, Luce JM, Sprung CL, Rinaldi JE, Tate RM, Sibbold WJ, Kariman K, Higgins S, Bradley R, Metz CA, Harris TR, Brigham KL. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317: 1565–70.PubMedCrossRefGoogle Scholar
  82. 82.
    Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ Jr. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta analysis. Crit Care Med 1995; 23: 1294–303.PubMedCrossRefGoogle Scholar
  84. 84.
    Bollaert PE, Charpentier C, Levy B, Debouverie M, Aduibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645–50.PubMedCrossRefGoogle Scholar
  85. 85.
    Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomised, double-blind, single-center study. Crit Care Med 1999; 27: 723–32.PubMedCrossRefGoogle Scholar
  86. 86.
    Nydegger UE. Sepsis and polyspecific intravenous immunoglobulins. J Clin Apheresis 1997; 12: 93–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Werdan K, Pilz G. Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol 1996; 104 (Suppl 1): 83–90.PubMedGoogle Scholar
  88. 88.
    Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, SadoffJC, Douglas H, Braude AI. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307: 1225–30.PubMedCrossRefGoogle Scholar
  89. 89.
    Zanetti G, Glauser MP, Baumgartner J. Use of immunoglobulins in prevention and treatment of infection in critically ill patients: review and critique. Rev Infect Dis 1991; 13: 985–92.PubMedCrossRefGoogle Scholar
  90. 90.
    Calandra T, Glauser MP, Schellekens J, Verhoef J. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double blind, randomized trial. J Infect Dis 1988; 158: 312–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia colfi J5: a prospective, double blind study. J5 Study Group J Infect Dis 1992; 165: 695–701.Google Scholar
  92. 92.
    Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, Allen E, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR. Treatment of gram negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double blind, placebo controlled trial. The HA-1A Sepsis Study Group N Engl J Med 1991; 324: 429–36.CrossRefGoogle Scholar
  93. 93.
    Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, Maclntyre N, Schein RM. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995; 23: 994–1006.PubMedCrossRefGoogle Scholar
  94. 94.
    Greenman RL, Schein RM, Martin MA, Wenzel RP, Macintyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram negative sepsis. The XOMA Sepsis Study Group. JAMA 1991; 266: 1097–102.PubMedCrossRefGoogle Scholar
  95. 95.
    McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double blind, placebo controlled trial. CHESS Trial Study Group. Ann Intern Med 1994; 121: 1–5.PubMedCrossRefGoogle Scholar
  96. 96.
    Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC. Efficacy and safety of monoclonal antibody to human tumor necrosis factor (in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273: 934–41.PubMedCrossRefGoogle Scholar
  97. 97.
    Cohen J, Cadet J. INTERSEPT: an international, multicenter, placebo controlled trial of monoclonal antibody to human tumor necrosis factor-(in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996; 24: 1431–40.PubMedCrossRefGoogle Scholar
  98. 98.
    Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderiak R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S. Double blind, randomised, controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. NORASEPT II Study Group Lancet 1998; 351: 929–33.Google Scholar
  99. 99.
    Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 1997; 277: 1531–8.PubMedCrossRefGoogle Scholar
  101. 101.
    Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334: 1697–702.PubMedCrossRefGoogle Scholar
  102. 102.
    Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M. Cnfirmatory interleukin1 receptor antagonist trial in severe sepsis: a phase III randomized, double blind, placebo controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group Crit Care Med 1997; 25: 1115–24.Google Scholar
  103. 103.
    Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines D, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double blind, placebo controlled trial. Phase III rhiL-lra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836–43.PubMedCrossRefGoogle Scholar
  104. 104.
    Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira JP, de Vathaire F, Guinot P. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double blind, placebo controlled, multicenter clinical trial. Crit Care Med 1994; 22: 1720–8.PubMedGoogle Scholar
  105. 105.
    Dhainaut JFA, Tenaillon A, Hemmer M, Damas P, Le Tulzo Y, Radermacher P, Schaller MD, Sollet JP, Wolff M, Holzapfel L, Zeni F, Vedrinne JM, de Vathaire F, Gourley ML, Guinot P. Mira JP. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram negative bacterial sepsis: a phase III randomised, double blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 1998; 26: 1963–71.PubMedCrossRefGoogle Scholar
  106. 106.
    Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr, Knaus WA, Levy H, Matuschak GM, Shanies HM, Taylor RW, Rodell TC. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomised, double blind, placebo controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 1997; 277: 482–7.PubMedCrossRefGoogle Scholar
  107. 107.
    Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336: 912–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Haupt MT, Jastremski MS, Clemmer TP, Metz CA, Goris GB. Effects of ibuprofen in patients with severe sepsis: a randomized, double blind, multicenter study. The ibuprofen Study Group. Crit Care Med 1991; 19: 1339–47.PubMedCrossRefGoogle Scholar
  109. 109.
    Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993; 21: 1635–42.PubMedCrossRefGoogle Scholar
  110. 110.
    Peake SL, Moran JL, Leppard PI. N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. Crit Care Med 1996; 24: 1302–10.PubMedCrossRefGoogle Scholar
  111. 111.
    Molnar Z, Shearer E, Lowe D. N-Acetylcysteine treatment to prevent the progression of multisystem organ failure: a prospective, randomised, placebo controlled study. Crit Care Med 1999; 27: 1100–4.PubMedCrossRefGoogle Scholar
  112. 112.
    Landry DW, Levin HR, Gallant EM, Seo S, D’Alessandro D, Oz MC, Oliver JA. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25: 1279–82.PubMedCrossRefGoogle Scholar
  113. 113.
    Landry DW, Levin FIR, Gallant EM, Ashton RC Jr, Seo S, D’Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95: 1122–5.PubMedCrossRefGoogle Scholar
  114. 114.
    Petros A, Bennett D, Valiance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338: 1557–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Lorente JA, Landin L, de Pablo R, Renes E, Liste D. L-arginine pathway in the sepsis syndrome. Crit Care Med 1993; 21: 1287–95.Google Scholar
  116. 116.
    Schilling J, Cakmakci M, Battig U, Geroulanos S. A new approach in the treatment of hypotension in human septic shock by NG-monomethyl-L-arginine, an inhibitor of the nitric oxide synthetase. Intensive Care Med 1993; 19: 227–31.PubMedCrossRefGoogle Scholar
  117. 117.
    Preiser JC, Lejeune P, Roman A, Carlier E, DeBacker D, Leeman M, Kahn RJ, Vincent JL. Methylene blue administration in septic shock: a clinical trial. Crit Care Med 1995; 23: 259–64.PubMedCrossRefGoogle Scholar
  118. 118.
    Cobb JP. Use of nitric oxide synthase inhibitors to treat septic shock: the light has changed from yellow to red. Crit Care Med 1999; 27: 855–6.PubMedCrossRefGoogle Scholar
  119. 119.
    Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo controlled, double blind trial. Crit Care Med 1999; 27: 807–14.PubMedCrossRefGoogle Scholar
  120. 120.
    Stauback KH, Schroder J, Stuber F, Gehrke K, Traumann E, Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomised, double blind, placebo controlled study. Arch Surg 1998; 133: 94–100.CrossRefGoogle Scholar
  121. 121.
    Boeuf B, Gauvin F, Guerguerian AM, Farrell CA, Lacroix J, Jenicek M. Therapy of shock with naloxone: a meta-analysis. Crit Care Med 1998; 26: 1910–6.PubMedCrossRefGoogle Scholar
  122. 122.
    Nelson S, Belknap SM, Carlson RW, Dale D, DeBoisblanc B, Farkas S, Fotheringham N, Ho H, Marne T, Morahhed H, Root R, Wilson J. A randomised controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J Infect Dis 1998; 178: 1075–80.CrossRefGoogle Scholar
  123. 123.
    Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 1992; 101: 816–23.PubMedCrossRefGoogle Scholar
  124. 124.
    Rintala E, Seppala OP, Kotkainen P, Pettila V, Rasi V. Protein C in the treatment of coagulopathy in meningococcal disease. Crit Care Med 1998; 26: 965–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Takata J, Ruokenon E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341: 785–92.CrossRefGoogle Scholar
  126. 126.
    Brigden ML, Pattullo AL. Prevention and management of overwhelming postsplenectomy infections—an update. Crit Care Med 1999; 27: 836–42.PubMedCrossRefGoogle Scholar
  127. 127.
    Alexander JW. Prevention of bacterial translocation with early enteral feeding–a feasible approach? In: Faist E, Meakins JL, Schildberg FW, eds. Host Defense Dysfunction in Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches. Berlin, New York: Springer-Verlag 1993; 903–9.CrossRefGoogle Scholar
  128. 128.
    Rush BF Jr, Sori AJ, Murphy TF, Smith S, Flanagan JJ Jr, Machiedo GW. Endotoxemia and bacteremia during hemorrhagic shock. The link between trauma and sepsis? Ann Surg 1988; 207: 549–54.PubMedCrossRefGoogle Scholar
  129. 129.
    Ramsay G, van Saene RH. Selective decontamination in intensive care and surgical practice: where are we? World J Surg 1998; 22: 164–70.Google Scholar
  130. 130.
    Wray G, Hinds C. Determinants of outcome from sepsis and septic shock. In: Vincent JL, ed. Yearbook of Intensive Care and Emergency Medicine, Springer 1997; 168–79.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Geoffrey M. Clarke
    • 1
  1. 1.Royal Perth HospitalPerthWestern Australia

Personalised recommendations